AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®

Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas, NV.

Congress details:

The Venetian Convention & Expo Center
201, Sands Avenue, 89169, Las Vegas, Nevada, United States

April 26 – 28, 2025

The full congress schedule can be viewed here

The congress will feature four abstract presentations on Telix’s late-stage and commercial theranostic programs.
 
Presentations cover:

  • ProstACT Global Phase 3 study of TLX591 (177Lu rosopatamab tetraxetan), Telix’s first-in-class PSMA targeting radio antibody-drug conjugate (rADC) therapy candidate for prostate cancer,
  • Cost-effectiveness analysis of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET/CT to guide management of small renal masses,
  • Enhancing sensitivity of Illuccix® (68Ga-PSMA-11) PET/CT with newer higher resolution cameras, and
  • Pathology reported prostatectomy margin status does not predict the odds of PSMA-PET-detected fossa recurrence.

The Company will also present two thought leadership sessions at the Telix Product Theater, featuring key opinion leaders in urologic oncology – one on Illuccix® imaging for the staging of prostate cancer, and a second on the future of kidney cancer detection and management.
 
Visit booth #1360 to discuss Telix’s extensive theranostic portfolio in urology targeting PSMA, CAIX and FAP across prostate, kidney and bladder cancers, its investigational pan-cancer programs, associated medical technologies, and opportunities for collaboration. 

See below for full details

Presentations
Scott Tagawa, MD

Weill Cornell Medicine

ProstACT Global: A Phase 3 study of TLX591 (177Lu-rosopatamab) plus standard of care vs. standard of care alone in patients with metastatic castration-resistant prostate cancer

Monday, April 28 | 1:00 PM – 1:08 PM (PDT
Location: Hall C, The Square, Learning Lab

Clinical Trials in Progress: Prostate & Kidney Cancer
Pratik Kanabur, MD

UCLA Department of Urology

Cost-effectiveness analysis of TLX250-CDx (89Zr-girentuximab) PET/CT to guide management of small renal masses

April 26 | 3:30 PM – 5:30 PM (PDT)
Location: Cassanova 501

Kidney Cancer: Localized: Surgical Therapy II
Maya Ataya, MD

Indiana University

Can the sensitivity of Illuccix (68Ga-PSMA-11) PET/CT be enhanced with newer higher resolution PET/CT cameras?

Monday, April 28 | 1:00 PM – 3:00 PM (PDT)
Location: Marco Polo 701

Prostate Cancer Detection & Screening III
Maya Ataya, MD

Indiana University

Pathology reported prostatectomy margin status does not predict the odds of PSMA-PET-detected fossa recurrence.

Tuesday, April 29 | 9:30 AM – 11:30 AM (PDT)
Location: Cassanova 501

Prostate Cancer: Advanced (Including Drug Therapy) III
Sanoj Punnen, MD

The University of Miami Health System

Illuccix® for 68Ga PSMA-11 imaging for the staging of prostate cancer

Monday, April 28 | 11:30 AM (PDT)
Location: Telix AUA Product Theater, Science & Technology Hall Booth #2001

Dan Joyce, MD

Vanderbilt University Medical Center

The future of kidney cancer detection and management

Sunday, April 27 | 2:30 PM (PDT)
Location: Telix AUA Product Theater, Science & Technology Hall Booth #2001

Presenters